Tyrosine kinase inhibitor (TKI)‐induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

Advanced preclinical screening methods, including cultured cardiomyocytes and functional imaging in animal models, are necessary to bridge the gap in predicting TKI-induced cardiotoxicity.